Ex Vivo Normothermic Perfusion in Kidney Transplantation.

Exclusion Criteria

• •1. Two or more previous kidney transplantations
• •2. Dual kidney transplantation or multivisceral transplantation (e.g. a pancreas-kidney transplantation)
• •3. Recipients of an organ with any of the following characteristics:
• •1. Expected cold ischemia time before EVNP \> 20 hours
• •2. Organ from hepatitis B surface antigen-positive or hepatitis C viremic donor
• •3. Organ with multiple arteries
• •4. Recipients with body mass index (BMI) \> 40 kg/m2
• •5. Diagnosis of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis with high recurrence risk after transplantation in the eyes of the investigator.
• •6. Diagnosis of atypical hemolytic-uremic syndrome or thrombotic microangiopathy at the moment of inclusion
• •7. Diagnosis of antiphospholipid syndrome at the moment of inclusion
• •8. Panel-reactive antibodies (PRA) score \> 50%
• •9. Known allergies to any of the components of the perfusate
• •10. Preexisting vascular disease that represents an extraordinary technical difficulty for the transplantation in the opinion of the investigator
• •11. Presence of clinically relevant donor-specific anti-HLA antibodies
• •12. ABO incompatibility
• •13. History of alcohol or drug abuse in the last two years
• •14. Use of normothermic regional perfusion during the organ harvesting process
• •15. Participation of the patient in another study or clinical trial.